Akebia Therapeutics, Inc. Earnings Recaps
Q1 2026
May 8, 2026
Akebia’s shares fell 21.6% following the quarter as investors reacted negatively to an unexpectedly cautious outlook and indicators of deceleration in key metrics despite some progress in product launch and clinical data.
Key takeaways
- Vafseo net product revenue reached nearly $16 million in Q1, the highest quarter to date, reflecting initial growth from expanded prescribing and observed dosing protocols.
- Clinical evidence continues to build with published INNOVATE trial data showing reduced hospitalization risks and costs for Vafseo-treated patients versus ESA comparators.
- The company emphasized ongoing trials VOCAL and VOICE, with data expected by year-end 2026 and early 2027, respectively, to validate Vafseo’s clinical profile and support future adoption.
- R&D pipeline advances include Phase II studies for praliciguat in FSGS and Abribafisp targeting complement-mediated kidney diseases, but these remain early-stage with no imminent commercial impact.
- Despite these developments, investor disappointment likely stemmed from tempered forward guidance or lack of clearer acceleration in revenue growth and further margin improvement.
Q3 2025
Nov 11, 2025
Akebia's Q3 2025 results highlight promising launch momentum for Vafseo despite revenue of $14.3 million, driven by strong prescriber interest and increasing patient access.
Key takeaways
- Vafseo has generated more prescriptions in its first 41 weeks than any recent dialysis launch, indicating notable market acceptance.
- Patient accessibility increased from 40,000 to nearly 70,000, aided by partnerships with DaVita and smaller providers.
- Recent data presented at the ASN meeting suggests Vafseo may lower mortality and hospitalization risks for dialysis patients, bolstering its clinical differentiation.
- Plans are underway to engage with the FDA about a three-times-weekly dosing regimen, which could enhance patient adherence and facilitate broader adoption.
- Ongoing operational challenges to integrate Vafseo into existing dialysis protocols are being addressed to improve therapy availability.